Compile Data Set for Download or QSAR
maximum 50k data

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB (change energy unit to kcal/mol)

Found 12 hits in this display   

TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50:  150nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50:  150nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent